Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection ... (machinery can generate toxic by-products...)

Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology

Date:12/4/2008

machinery can generate toxic by-products -- "oxygen free radicals" -- that can chemically damage surrounding molecules, including mtDNA. Damaged mtDNA causes the production of faulty or decreased OX-PHOS machinery, which then can increase the generation of oxygen free radicals, and so a vicious cycle is triggered that ultimately leads to a reduced energy supply ATP. The amount of damaged mtDNA thus is an inverse measure of cellular health: the less damage the healthier and the more damage the less healthy a cell is.

Transgenomic has specialized in the molecular diagnostics of mitochondrial disorders including whole mitochondrial genome sequence and pathogenic point mutation analysis, as well as assessment of nuclear genes associated with mitochondrial function, such as DNA polymerase gamma (POLG). In addition to the mtDNA damage assay, Transgenomic is developing other tests to assess mtDNA copy number and deletion.

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
2. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
3. William F. McMurry - Lead Class Counsel Obtains $16.4 Million Settlement for Elderly Clients
4. China Medicine Corporation Obtains Australian Patent for rADTZ
5. DRAXIS Obtains Final Order for Proposed Arrangement
6. DRAXIS Obtains Interim Order for Proposed Arrangement
7. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
8. Aspreva obtains shareholder approval for acquisition by Galenica
9. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. BET Networks Joins the International Call to Stop the Spread of HIV on World AIDS Day Monday, December 1 with a Special Episode of 106 & PARK Followed by BET News Exclusive ARE YOU POSITIVE?

Post Your Comments:

Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection ...(machinery can generate toxic by-products...),Health